The Phase III TRIUMpH trial demonstrated that tegoprazan, a novel potassium-competitive acid blocker (P-CAB), provided significantly better maintenance of healing in patients with erosive esophagitis over 24 weeks compared to lansoprazole, including severe cases (LA Grades C/D). The drug shows a favorable safety profile, and FDA submission is planned for late 2025.
Call for Appointment
(214) 831-2521
Address
3417 Spectrum Boulevard #200 Richardson, TX